Das Mikrobiom als Drehscheibe für Nebenwirkungen der Protonenpumpenhemmer-Therapie

Zusammenfassung

Protonenpumpenhemmer werden seit etwa 30 Jahren erfolgreich gegen magensäureassoziierte Erkrankungen, wie peptische Ulzera oder Refluxerkrankungen, eingesetzt. Durch ihre kovalente Bindung an die Protonenpumpen in den Parietalzellen des Magens kann die Magensäureproduktion effektiv reduziert und die therapeutische Wirkung der Protonenpumpenhemmer entfaltet werden. Auf diese Weise wird aber auch ein wichtiger Bestandteil der unspezifischen Immunabwehr ausgeschaltet, der den Körper – und vor allem das Darmmikrobiom – vor mit der Nahrung aufgenommenen Pathogenen oder eingeschwemmten Mundkeimen schützt. Daraus ergeben sich Veränderungen des Darmmikrobioms, wie eine Reduktion der Diversität des Mikrobioms oder eine Fehlbesiedelung des Dünndarms, die mit verschiedenen Nebenwirkungen der Protonenpumpen-(Langzeit-)Therapie, wie einem erhöhten Risiko für Clostridium-difficile-Infektionen oder gastrointestinalen Beschwerden, assoziiert sind. Bei Menschen mit Leberzirrhose bspw. ist die Einwanderung von oralen Bakterien in den Darm mit intestinaler Inflammation und Permeabilität verbunden und kann als Biomarker für das 3-Jahres-Überleben herangezogen werden. Mikrobiomassoziierte Nebenwirkungen sollten daher in den Diskurs über die Risiken von Langzeittherapien mit Protonenpumpenhemmern und dem Abwägen von Alternativen miteinbezogen werden.

Abstract

Proton pump inhibitors are valuable treatment options for gastric acid associated diseases, such as peptic ulcer disease or reflux diseases. Due to their irreversible inhibition of the proton pumps in the parietal cells of the stomach, gastric acid secretion can be effectively reduced. With the reduction in gastric acid, however, proton pump inhibitors also block a highly conserved, crucial part of the unspecific immune system. The gastric barrier protects the body – and here mainly the intestinal microbiome – from food-borne pathogens and oral bacteria that can reach more distal parts of the gastrointestinal tract during proton pump inhibitor therapy. Resulting changes in the intestinal microbiome, such as the reduction in microbial diversity or small intestinal bacterial overgrowth, can be linked to side effects of (long-term) proton pump inhibitor therapy, such as the increased risk of Clostridium difficile infections or gastrointestinal discomfort. In liver cirrhosis patients, the increase in oral bacteria in the intestine is associated with intestinal inflammation and permeability, and can even be used as a biomarker for 3-year liver related mortality. Therefore, microbiome-mediated side effects should be included in the risk assessment of proton pump inhibitor therapy and the evaluation of potential alternatives.

Schlüsselwörter

Mikrobiom - medikamenteninduzierte Dysbiose - PPI-Nebenwirkungen

Key words

drug-induced dysbiosis - PPI side effects - microbiome

Publication History

Article published online:
16 December 2020

• Literatur

• 1 Savarino V, Dulbecco P, de Bortoli N. et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med 2017; 37: 19-24 doi:10.1016/j.ejim.2016.10.007
• 2 Ahrens D, Chenot JF, Behrens G. et al. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 2010; 66: 1265-1271 doi:10.1007/s00228-010-0871-9
• 3 Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol 2016; 28: 420-425 doi:10.1097/bor.0000000000000291
• 4 Poly TN, Islam MM, Yang HC. et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 2019; 30: 103-114 doi:10.1007/s00198-018-4788-y
• 5 Lam JR, Schneider JL, Zhao W. et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310: 2435-2442 doi:10.1001/jama.2013.280490
• 6 Srinutta T, Chewcharat A, Takkavatakarn K. et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine 2019; 98: e17788 doi:10.1097/md.0000000000017788
• 7 Lambert AA, Lam JO, Paik JJ. et al. Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0128004 doi:10.1371/journal.pone.0128004
• 8 Jordakieva G, Kundi M. Country-wide medical records infer increased allergy risk of gastric acid inhibition. Nat Commun 2019; 10: 3298 doi:10.1038/s41467-019-10914-6
• 9 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 2017; 14: 697-710 doi:10.1038/nrgastro.2017.117
• 10 Geevasinga N, Coleman PL, Webster AC. et al. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4: 597-604 doi:10.1016/j.cgh.2005.11.004
• 11 Cheung KS, Chan EW, Wong AYS. et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28-35 doi:10.1136/gutjnl-2017-314605
• 12 Kuipers EJ, Lundell L, Klinkenberg-Knol EC. et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-1022 doi:10.1056/nejm199604183341603
• 13 Li M, Luo Z, Yu S. et al. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine 2019; 98: e14422 doi:10.1097/md.0000000000014422
• 14 Heather JM, Chain B. The sequence of sequencers: The history of sequencing DNA. Genomics 2016; 107: 1-8 doi:10.1016/j.ygeno.2015.11.003
• 15 Callahan BJ, McMurdie PJ, Rosen MJ. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 2016; 13: 581-583 doi:10.1038/nmeth.3869
• 16 Zhernakova A, Kurilshikov A, Bonder MJ. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016; 352: 565-569 doi:10.1126/science.aad3369
• 17 Su T, Lai S, Lee A. et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018; 53: 27-36 doi:10.1007/s00535-017-1371-9
• 18 Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 483-490 doi:10.1016/j.cgh.2012.12.011
• 19 Sieczkowska A, Landowski P, Zagozdzon P. et al. Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor. J Pediatr 2015; 166: 1310-1312.e1 doi:10.1016/j.jpeds.2015.01.004
• 20 Washio E, Esaki M, Maehata Y. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol 2016; 14: 809-815.e1 doi:10.1016/j.cgh.2015.10.022
• 21 Wallace JL, Syer S, Denou E. et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322 1322.e1–5 doi:10.1053/j.gastro.2011.06.075
• 22 Seto CT, Jeraldo P, Orenstein R. et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014; 2: 42 doi:10.1186/2049-2618-2-42
• 23 Imhann F, Bonder MJ, Vich Vila A. et al. Proton pump inhibitors affect the gut microbiome. Gut 2016; 65: 740-748 doi:10.1136/gutjnl-2015-310376
• 24 Daly AJ, Baetens JM, De Baets B. Ecological Diversity: Measuring the Unmeasurable. Mathematics 2018; 6: 119 doi:10.3390/math6070119
• 25 He X, McLean JS, Guo L. et al. The social structure of microbial community involved in colonization resistance. ISME J 2014; 8: 564-574 doi:10.1038/ismej.2013.172
• 26 Case TJ. Invasion resistance arises in strongly interacting species-rich model competition communities. Proc Natl Acad Sci U S A 1990; 87: 9610-9614
• 27 Buffie CG, Bucci V, Stein RR. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517: 205-208 doi:10.1038/nature13828
• 28 Chang JY, Antonopoulos DA, Kalra A. et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435-438 doi:10.1086/525047
• 29 Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056 quiz 2057 doi:10.1111/j.1572-0241.2007.01275.x
• 30 Trifan A, Stanciu C, Girleanu I. et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23: 6500-6515 doi:10.3748/wjg.v23.i35.6500
• 31 Tsuda A, Suda W, Morita H. et al. Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. Clin Transl Gastroenterol 2015; 6: e89 doi:10.1038/ctg.2015.20
• 32 Bajaj JS, Cox IJ, Betrapally NS. et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014; 307: G951-G957 doi:10.1152/ajpgi.00268.2014
• 33 Jackson MA, Goodrich JK, Maxan ME. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65: 749-756 doi:10.1136/gutjnl-2015-310861
• 34 Clooney AG, Bernstein CN, Leslie WD. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther 2016; 43: 974-984 doi:10.1111/apt.13568
• 35 Freedberg DE, Toussaint NC, Chen SP. et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology 2015; 149: 883-885.e9 doi:10.1053/j.gastro.2015.06.043
• 36 Horvath A, Rainer F, Bashir M. et al. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep 2019; 9: 12000 doi:10.1038/s41598-019-48352-5
• 37 Bajaj JS, Heuman DM, Hylemon PB. et al. The Cirrhosis Dysbiosis Ratio defines Changes in the Gut Microbiome Associated with Cirrhosis and its Complications. J Hepatol 2014; 60: 940-947 doi:10.1016/j.jhep.2013.12.019
• 38 Stadlbauer V, Komarova I, Klymiuk I. et al. Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis. Liver International 2020; 40: 866-877 doi:10.1111/liv.14382
• 39 Dam G, Vilstrup H, Watson H. et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016; 64: 1265-1272 doi:10.1002/hep.28737
• 40 Dultz G, Piiper A, Zeuzem S. et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther 2015; 41: 459-466 doi:10.1111/apt.13061
• 41 Xie Y, Bowe B, Li T. et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 2017; 7: e015735 doi:10.1136/bmjopen-2016-015735
• 42 Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10: 528-534 doi:10.1007/s11894-008-0098-4
• 43 Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987; 28: 96-107 doi:10.1136/gut.28.1.96
• 44 Llorente C, Jepsen P, Inamine T. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun 2017; 8: 837 doi:10.1038/s41467-017-00796-x
• 45 Horvath A, Bausys A. Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol 2020; DOI: 10.1245/s10434-020-08678-1.
• 46 Maier L, Pruteanu M, Kuhn M. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555: 623-628 doi:10.1038/nature25979
• 47 Saniee P, Shahreza S, Siavoshi F. Negative Effect of Proton-pump Inhibitors (PPIs) on Helicobacter pylori Growth, Morphology, and Urease Test and Recovery after PPI Removal–An In vitro Study. Helicobacter 2016; 21: 143-152 doi:10.1111/hel.12246
• 48 Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969; 54: 237-249
• 49 Belei O, Olariu L, Dobrescu A. et al. Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?. J Neurogastroenterol Motil 2018; 24: 51-57 doi:10.5056/jnm17059
• 50 Horvath A, Leber B, Feldbacher N. et al. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep 2020; 10: 2723 doi:10.1038/s41598-020-59550-x